Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Gene Therapy for Ovarian Cancer - 2018-2022 Pipeline Analysis Report - Research and Markets

Research and Markets
Posted on: 16 Jan 18

The "Gene Therapy for Ovarian Cancer - A Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.

Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products. However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.

Gene therapy is emerging as one of the most exciting approaches for the treatment of ovarian cancer. Replacement gene therapy, which replaces faulty genes with normal ones in the body, is particularly promising and currently gaining attention. It has potential to cure ovarian cancer and can be used as a promising option for long-lasting treatment.

Key vendors

  • Takara Bio
  • VBL
  • Therapeutics
  • Targovax
  • CELSION
  • Lokon Pharma
  • SiBiono GeneTech
  • Advantagene

Market trends

  • The adoption of replacement gene therapy

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

For more information about this report visit https://www.researchandmarkets.com/research/zwnzsw/gene_therapy_for?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180116005963/en/

Business Wire
www.businesswire.com

Last updated on: 16/01/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.